Amgen’s trial drug for gastric cancer patients helps them live longer
HQ Team June 30, 2025: Amgen Inc.’s experimental drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 30, 2025: Amgen Inc.’s experimental drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer.
The US drug regulator has approved Amen’s biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug.
HQ Team May 17, 2024: The US Food and Drug Administration has cleared Amgen’s drug to treat adult patients in the extensive stages.
Amgen Inc, one of the world's largest biotechnology companies, will acquire Dublin-based Horizon Therapeutics Plc for $27.8 billion.